Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.
Fractyl’s Revita hit its six-month goal in a sham-controlled pivotal trial, and the FDA filing is planned for late Q4 2026.
Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.
John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...
Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.
Steven Austad and Arlan Richardson explore animal longevity, fasting, GLP-1s and biomarkers to reveal what could translate to ...
Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...
Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.
Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.
Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results